C94.22
Acute megakaryoblastic leukemia, in relapse
Clinical Classification Guidelines
Medical Intelligence & Overview
Acute megakaryoblastic leukemia (AMKL) is a rare and aggressive type of leukemia characterized by the overproduction of immature megakaryoblasts, which are precursors to blood cells called megakaryocytes. When the disease returns after treatment, it is referred to as a relapse. The ICD-10 code C94.22 specifically denotes cases where AMKL has relapsed. This condition requires prompt medical attention to manage symptoms and consider further treatment options. Patients and caregivers should gain a clear understanding of the disease to navigate the treatment process effectively.
Causes & Symptoms
Clinical Causes: Previous chemotherapy or radiation therapy for other cancers Genetic disorders such as Down syndrome Exposure to certain chemicals or toxins Family history of hematologic cancers Certain inherited genetic mutations
Key Symptoms: Fatigue and weakness Pale skin due to anemia Easy bruising or bleeding (such as nosebleeds, bleeding gums) Frequent infections or fever Shortness of breath Bone pain or tenderness Swelling in the joints or abdomen from enlarged spleen or liver
Diagnostic & Treatment
Diagnosis Path: Complete blood count (CBC) to assess blood cell levels Bone marrow biopsy to examine the presence of leukemia cells and determine if the disease has returned Flow cytometry and cytogenetic testing to identify specific cell surface markers and genetic mutations Imaging tests such as ultrasound or MRI may be used to evaluate organ involvement Molecular testing to identify genetic abnormalities associated with AMKL relapse
Treatment Protocols: Intensive chemotherapy to induce remission Targeted therapies that focus on specific genetic mutations if applicable Stem cell (bone marrow) transplant to replace diseased marrow with healthy cells Supportive care measures like blood transfusions and antibiotics to prevent or treat infections Clinical trials exploring promising new treatments could be considered for eligible patients
Clinical Advice & FAQs
Billing Guidance
Is C94.22 a billable ICD-10 code?
Yes, C94.22 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report C94.22?
Clinical documentation must specify the nature of Acute megakaryoblastic leukemia, in relapse and any associated comorbidities for accurate reporting.
Cite this Clinical Reference